Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

4.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.3K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Case of Pleomorphic Carcinoma of the Lung Complicated by Anti-HMGCR Antibody-Positive Necrotizing Myositis.

The Tokai journal of experimental and clinical medicine·2026
Same author

A Case of Anti-SRP Antibody-Positive Necrotizing Myopathy That Initially Presented With Raynaud's Phenomenon and a Digital Ulcer.

The Journal of dermatology·2025
Same author

Intravenous Regeneration-associated Cell Transplantation Enhances Tissue Recovery in Mice with Acute Ischemic Stroke.

The Keio journal of medicine·2024
Same author

Elevation of inositol pyrophosphate IP<sub>7</sub> in the mammalian spinal cord of amyotrophic lateral sclerosis.

Frontiers in neurology·2024
Same author

[Effect of safinamide on morning-off phenomenon in elderly patients with Parkinson's disease].

Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics·2024
Same author

Case report: Corneal endothelial degeneration and optic atrophy in dentatorubral-pallidoluysian atrophy quantified by specular micrography and optical coherence tomography.

Frontiers in neurology·2022
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Related Experiment Video

Updated: Mar 19, 2026

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells
07:56

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

Published on: July 22, 2019

12.0K

[G-CSF treatment].

Atsushi Mizuma, Shunya Takizawa

    Nihon Rinsho. Japanese Journal of Clinical Medicine
    |June 24, 2016
    PubMed
    Summary
    This summary is machine-generated.

    Granulocyte-colony stimulating factor (G-CSF) shows neuroprotective effects in ischemic stroke. However, its clinical efficacy requires further large-scale studies to confirm benefits and explore combination therapies.

    More Related Videos

    Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
    10:24

    Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

    Published on: October 5, 2015

    12.9K
    Isolation of Exosome-Enriched Extracellular Vesicles Carrying Granulocyte-Macrophage Colony-Stimulating Factor from Embryonic Stem Cells
    12:02

    Isolation of Exosome-Enriched Extracellular Vesicles Carrying Granulocyte-Macrophage Colony-Stimulating Factor from Embryonic Stem Cells

    Published on: November 11, 2021

    4.7K

    Related Experiment Videos

    Last Updated: Mar 19, 2026

    Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells
    07:56

    Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

    Published on: July 22, 2019

    12.0K
    Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System
    10:24

    Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

    Published on: October 5, 2015

    12.9K
    Isolation of Exosome-Enriched Extracellular Vesicles Carrying Granulocyte-Macrophage Colony-Stimulating Factor from Embryonic Stem Cells
    12:02

    Isolation of Exosome-Enriched Extracellular Vesicles Carrying Granulocyte-Macrophage Colony-Stimulating Factor from Embryonic Stem Cells

    Published on: November 11, 2021

    4.7K

    Area of Science:

    • Neuroscience
    • Immunology
    • Pharmacology

    Context:

    • Ischemic stroke presents significant challenges in acute phase neuroprotection.
    • Granulocyte-colony stimulating factor (G-CSF) has demonstrated potential neuroprotective, anti-apoptotic, anti-inflammatory, and anti-immune effects in preclinical models.
    • Previous clinical trials have suggested safety and some clinical improvements with G-CSF in stroke patients.

    Purpose:

    • To evaluate the current evidence on the efficacy of G-CSF in acute ischemic stroke.
    • To identify the need for further research to establish G-CSF's therapeutic role.

    Summary:

    • G-CSF exhibits various beneficial properties, including neuroprotection and anti-inflammatory actions, relevant to acute ischemic stroke.
    • Clinical trials indicate G-CSF is safe and may improve symptoms and reduce infarct volume.
    • However, definitive proof of G-CSF efficacy in acute ischemic stroke is lacking due to limitations in study design and patient numbers.

    Impact:

    • Further large-scale, well-designed clinical trials are necessary to confirm G-CSF's effectiveness.
    • Future research should focus on uniform patient populations, infarct sizes, and stroke subtypes.
    • Combination therapy with G-CSF and thrombolysis represents a promising avenue for future clinical investigations.